Skip to main content
New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
September 22, 2025
Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
September 17, 2025
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
July 30, 2025
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
May 7, 2025
Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI
March 31, 2025
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia
February 10, 2025
UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization
January 29, 2025
Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM
December 9, 2024
25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3
November 6, 2024
New Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®
November 4, 2024
